Sumitomo Mitsui Trust Group Inc. Has $1.51 Billion Holdings in Eli Lilly and Company $LLY

Key Points

• Sumitomo Mitsui Trust Group Inc. reduced its holdings in Eli Lilly to 1,933,101 shares, representing approximately $1.51 billion or 0.9% of its portfolio.
• Eli Lilly reported $6.31 earnings per share for the last quarter, exceeding estimates, with revenue rising 37.6% year-over-year to $15.56 billion.
• Analysts' price targets for Eli Lilly range from $700 to $1,100, with the stock currently holding a consensus rating of "Moderate Buy".

Sumitomo Mitsui Trust Group Inc. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,933,101 shares of the company's stock after selling 20,348 shares during the period. Eli Lilly and Company makes up 0.9% of Sumitomo Mitsui Trust Group Inc.'s portfolio, making the stock its 14th biggest position. Sumitomo Mitsui Trust Group Inc. owned approximately 0.20% of Eli Lilly and Company worth $1,506,910,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Brighton Jones LLC lifted its holdings in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock valued at $7,409,000 after purchasing an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC raised its stake in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock valued at $1,136,000 after buying an additional 40 shares during the period. Covestor Ltd raised its stake in Eli Lilly and Company by 24.9% in the first quarter. Covestor Ltd now owns 426 shares of the company's stock valued at $352,000 after buying an additional 85 shares during the period. GAMMA Investing LLC increased its stake in shares of Eli Lilly and Company by 25.8% during the first quarter. GAMMA Investing LLC now owns 18,000 shares of the company's stock worth $14,866,000 after purchasing an additional 3,696 shares during the period. Finally, Moran Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 1.4% during the first quarter. Moran Wealth Management LLC now owns 9,453 shares of the company's stock worth $7,807,000 after purchasing an additional 134 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Performance

LLY stock opened at $819.52 on Friday. The stock has a 50-day moving average price of $765.52 and a 200-day moving average price of $767.43. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market cap of $775.64 billion, a PE ratio of 53.55, a price-to-earnings-growth ratio of 1.16 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period last year, the company posted $3.92 EPS. The business's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. HSBC increased their target price on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Weiss Ratings reissued a "hold (c+)" rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Cantor Fitzgerald set a $925.00 price target on Eli Lilly and Company and gave the stock an "overweight" rating in a research report on Thursday, October 9th. JPMorgan Chase & Co. reduced their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday, September 16th. Finally, The Goldman Sachs Group raised their target price on Eli Lilly and Company from $876.00 to $879.00 and gave the company a "buy" rating in a report on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $938.61.

Insider Transactions at Eli Lilly and Company

In other news, EVP Daniel Skovronsky bought 1,000 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jamere Jackson bought 200 shares of Eli Lilly and Company stock in a transaction dated Friday, August 8th. The stock was purchased at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.